Capmatinib dihydrochloride hydrate |
| Catalog No.GC68828 |
Capmatinib (INC280; INCB28060) dihydrochloride hydrate is an effective, orally active, selective, ATP-competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride hydrate can inhibit the phosphorylation of c-MET and downstream effectors such as ERK1/2, AKT, FAK, GAB1 and STAT3/5 in the c-MET pathway. Capmatinib dihydrochloride hydrate effectively inhibits proliferation and migration of c-Met-dependent tumor cells and induces apoptosis. It exhibits anti-tumor activity in mouse models of cancer. Capmatinib dihydrochloride hydrate is mainly metabolized by CYP3A4 and aldehyde oxidase.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1865733-40-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *